Search Results

Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that UNITY® Vitreoretinal Cataract System and UNITY® Cataract System have received U.S. Food and Drug Administration 510 clearance.

Sight Sciences, Inc. today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision, LLC, Alcon Research, LLC, and Ivantis, Inc.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

Alcon, the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2023.

Eurofins CDMO Alphora Inc., a global Contract Development & Manufacturing Organization and part of the international network of Eurofins laboratories, is pleased to announce a significant expansion of its Drug Product Analytical Services Laboratory, increasing its footprint three-fold.

Mesa Laboratories, Inc. will not issue its 2024 financial results for the fourth quarter and the fiscal year ending March 31, 2024 as previously communicated.

bioLytical Laboratories Inc., a global leader in rapid diagnostic tests, proudly announces the immediate availability of its INSTI® HCV Antibody Test in the Australian market.

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED).